Research Article
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension-Based Chemotherapy in Sarcoma: A Multicenter, Retrospective Study
Table 2
Patient details with chemotherapy regimens and efficacy evaluation.
| No. | Age | Sex | If others, please specify | Cancer stage | Setting in which NDLS was used | NDLS chemotherapy used | Overall response as per the RECIST (1.1) |
| 1 | 48 | Male | High-grade pleomorphic sarcoma of mandible | III | Neoadjuvant setting | NDLS plus gemcitabine | CR | 2 | 42 | Male | Leiomyosarcoma | II | Adjuvant setting | NDLS plus gemcitabine | Not applicable | 3 | 35 | Male | Leiomyosarcoma | II | Adjuvant setting | NDLS plus gemcitabine | Not applicable | 4 | 55 | Female | Leiomyosarcoma | II | Adjuvant setting | NDLS plus gemcitabine | Not applicable | 5 | 49 | Female | Leiomyosarcoma | IV | Metastatic setting | NDLS plus gemcitabine | NE | 6 | 44 | Female | Leiomyosarcoma | IV | Metastatic setting | NDLS plus gemcitabine | SD | 7 | 46 | Female | Leiomyosarcoma | IV | Metastatic setting | NDLS plus gemcitabine | CR | 8 | 58 | Female | Leiomyosarcoma | IV | Metastatic setting | NDLS plus gemcitabine | PR | 9 | 59 | Male | Malignant fibrous histiocytoma of right thigh | IV | Metastatic setting | NDLS plus gemcitabine | PR | 10 | 52 | Female | Extraskeletal myxoid chondrosarcoma | IV | Metastatic setting | NDLS plus cyclophosphamide | PD | 11 | 19 | Female | Osteosarcoma of left femur | IV | Metastatic setting | NDLS plus gemcitabine | PD |
|
|
Note. Efficacy response was not evaluated for patients in adjuvant setting. Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NDLS, nanosomal docetaxel lipid suspension; NE, not evaluated.
|